{"id":"W4405034490","doi":"10.1182/blood-2024-193193","title":"Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor-Naïve Patients with Myelofibrosis","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Janus kinase inhibitor; Medicine; Internal medicine; Janus kinase 2; Janus; Janus kinase; Phases of clinical research; Janus kinase 1; Phase (matter); Oncology; Clinical trial; Chemistry; Bone marrow; Computer science; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005774667,0.0009126898,0.002211418,0.0004402708,0.0003799016,0.001478027,0.0008353107,0.0008542967,0.008070114],"category_scores_gemma":[0.003895411,0.0003874259,0.002440489,0.0006498884,0.000246378,0.0008937126,0.0005156401,0.001699617,0.001330175],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007299206,"about_ca_system_score_gemma":0.001111427,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001246259,"about_ca_topic_score_gemma":0.004145191,"domain_scores_codex":[0.9980984,0.001036508,0.0001938974,0.0001665469,0.0003039573,0.0002005658],"domain_scores_gemma":[0.9961271,0.0009563077,0.001288553,0.0002664198,0.0007342531,0.0006274658],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5319961,0.00795608,0.05800811,0.005313083,0.01278192,0.0004323429,0.000379238,0.003804803,0.02364165,0.0005156694,0.07260653,0.2825644],"study_design_scores_gemma":[0.3457915,0.1871104,0.3656631,0.001115011,0.01934206,0.001335781,0.0003275743,0.002417725,0.005944292,0.0009949737,0.06976511,0.0001924551],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8169487,0.05412623,0.003528316,0.006005498,0.00139012,0.005213399,0.09314381,0.0006420505,0.01900187],"genre_scores_gemma":[0.9005243,0.01037599,0.003728392,0.005429636,0.0009712245,0.003703319,0.06961859,0.0001363197,0.005512198],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008070114,"threshold_uncertainty_score":0.03053969,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01474007386459411,"score_gpt":0.2693564854403686,"score_spread":0.2546164115757745,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}